George Kesarios
Contributor since: 2008
Ceragon Networks: Here We Go Again
T2 Biosystems: Why The Bears Are Wrong
Apple's iPhone Revenue Shortfall In China Has Little To Do With Apple Itself
The FTC's Verdict Against Qualcomm Is A Victory For The Rule Of Law
Xunlei Limited: A Cloud Play For Less Than Its Net Cash
Sonos: An Attractive Valuation Play With Limited Risk
Pier 1 Imports: The Speculation Play Of The Year
4 Reasons To Buy Ceragon Networks Before Earnings
Why T2 Biosystems Is A Potential 10X Bagger
Fortress Biotech And Avenue Therapeutics, A Win-Win Trade
Yelp: Just Another Case Of An Overvalued Stock
ExOne: EPS Beat By A Wide Margin, But Shares Seem Fully Valued
Ceragon Networks Delivers, But Is A Further Rise In The Stock Justified?
How To Play Groupon After The Fall
scPharmaceuticals: A Speculation Play With A High Margin Of Safety
GoPro: Disappointing Margins Will Continue To Keep Shares Depressed
Micron: My Top Pick For 2019
T2 Biosystems Diagnostic Arsenal Expanded By Leaps And Bounds But No One Noticed
Aptevo Therapeutics: IXINITY Might Prove To Be A Never Expiring Option On The Company's Core Pipeline
Groupon: Waiting For Panic To Sink In
Why Snap Might Go Lower, Much Lower
Greek Banks Continue To Melt Like Butter
4 Worries I Have For 2018 And 2019
Greece: Forget About The Positive Headline News, Nothing Has Changed
$700 Gold Is Possible
Buy The Dip In ExOne, The Market Got It Wrong
Aptevo Therapeutics Continues To Impress
Ceragon Networks: Time For A Breather
GoPro: Fundamentals Continue To Deteriorate
T2 Biosystems Continues To Execute, Slowly But Surely
What You Always Knew About Facebook But Did Not Want To Admit
Why I Sold AMD